11th Annual CCF Foundation Conference Set for April 2024

December 2023, Vol 4, No 4

The Cholangiocarcinoma Foundation (CCF) is pleased to announce the 11th Annual Cholangiocarcinoma Foundation Conference in Salt Lake City, UT, April 17-19, 2024. The 3-day event includes a special patient and caregiver day and 2+ days of scientific sessions.

One of the most unique and fulfilling parts of the annual conference is the interaction between the research community, providers, patients, and caregivers, and we know this year will provide even more meaningful collaboration. Please go to https://cholangiocarcinoma.org/2024-annual-conference/ to register, and we look forward to seeing you in April.

10th Annual Cholangiocarcinoma Foundation Conference, April 2023

Wednesday: Patient and Caregiver Day and New

Basic Science Track

Wednesday is dedicated to patients and caregivers, and the day also offers a new basic science track for researchers and providers. Join us for a patient-friendly update on CCF’s programs, hear from patients and caregivers who are dealing with cholangiocarcinoma (CCA), and learn how you can get involved and help make a difference. Plus join us for some fun and wear green in support of all CCA patients.

Thursday: Scientific Day

Thursday is geared toward the scientific and medical community. Renowned experts in the field will present the latest advances in research, clinical advancements, and treatment options. Attendees will have the opportunity to engage with our speakers through live Q&A sessions, interactive breakout sessions, and networking events.

Friday: Scientific Day

Continuing the scientific focus, Friday offers more in-depth insights into the latest developments in CCA research and treatment. Explore breakthroughs, case studies, and emerging therapies contributing to our collective knowledge and progress in combating this disease.

“The conference brings together a multidisciplinary group of experts from around the world to present and exchange scientific ideas and proposals relating to the complex landscape of CCA. Global collaboration and high-quality research are hallmarks of the conference,” said Foundation CEO and Founder Stacie C. Lindsey. “A scientific conference that gives patients a seat at the table is the kind of inclusive, collaborative effort that makes this community unique. We are looking forward to a great conference.”

CCF is the leading global resource for CCA, a rare but deadly bile duct cancer. It strives to improve methods for early detection, advance treatment options, and improve quality of life and survival for CCA patients. The conference is the premier source for the presentation of research, innovative therapies, and patient education. In 2023, more than 1000 attendees participated in the conference.

Distinguished cochairs of the conference are Angela Lamarca, MD, PhD, MSc, Medical Oncology, Fundación Jiménez Diaz University Hospital; Mitesh J. Borad, MD, Program Leader—Gene and Virus Therapy Program, Mayo Clinic; and Do-Youn Oh, MD, PhD, Seoul National University Hospital. They are also among the more than 50 speakers who are presenting in designated sessions throughout the conference, which focuses on basic, translational, and clinical research.

In addition, the Foundation is honoring 3 individuals with its distinguished Mark R. Clements Award for volunteerism, community impact and vision, innovation, and collaboration. Mark R. Clements is the brainchild of the Foundation. He passed away from the disease in January 2006. His sister, Stacie C. Lindsey, and other family members carried out Mark’s wishes and founded the 501(c)(3) that is now moving into its 18th year in existence.

“The Mark R. Clements Awards are the highest honor awarded by the Foundation each year. As a CCA patient himself, Mark Clements was truly the inspiration and driving force around the creation of this Foundation,” said Lindsey.

A recent study estimates that by 2040, liver and bile duct cancer will be the third deadliest cancer in the United States.1 To advocate for much-needed funding and promote education about the disease, the Foundation hosts an Annual Conference each year to unite people who are fearlessly working to find a cure for CCA and share the latest education for CCA patients, caregivers, and professionals.

Reference

  1. Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open. 2021;4(4):e214708.

Related Items

CCF Celebrates Major Milestone in Connecting Patients and Caregivers to Mentorship Program
September 2023, Vol 4, No 3
The Cholangiocarcinoma Foundation (CCF) is celebrating the 1000th mentor–mentee match and 6 years of their mentoring program, CholangioConnect. CCF has developed unique resources to help patients and caregivers navigate their healthcare journeys.
10th Annual Cholangiocarcinoma Foundation Conference: International Collaboration, Patient Connections, Industry Updates
June 2023, Vol 4, No 2
Cancer investigators and clinicians from around the world connected with patients, caregivers, and industry officials at the foundation’s conference in Salt Lake City, UT.
CCF Welcomes a New Standard of Care
By Allison Deragon, Cholangiocarcinoma Foundation
March 2023, Vol 4, No 1
CCF discusses the approval of durvalumab for cholangiocarcinoma, a milestone that, it is hoped, will open doors for other innovative immunotherapy combinations.
Think Tank of Multidisciplinary Experts Develop Proposals to Improve Outcomes in Patients with CCA
December 2022, Vol 3, No 4
A group of 29 expert scientists and clinicians from the world’s leading academic institutions developed potentially transformative project proposals while gathered in Las Vegas for a 2-day meeting called Cure Cholangiocarcinoma Think Tank (C2T2).
International Cholangiocarcinoma Patient Registry Accelerates and Supports CCA Research
September 2022, Vol 3, No 3
The Cholangiocarcinoma Foundation hosts a patient registry, the International Cholangiocarcinoma Patient Registry (ICPR), that is a global database comprising patient medical histories and treatments for cholangiocarcinoma (CCA).
Clinical Trial Enrollment Challenges for Patients with Cholangiocarcinoma
By Reham Abdel-Wahab, MD, PhD; Samantha Pear
June/July 2022, Vol 3, No 2
There is a desperate need for patients with CCA to gain access to clinical trials to help improve survival.
The Cholangiocarcinoma Foundation’s Patient Advocacy Initiatives
March 2022, Vol 3, No 1
At the 2022 Cholangiocarcinoma Foundation (CCF) Annual Conference on February 22-25, Melinda Bachini, Director of Advocacy of CCF, provided an update about the foundation’s advocacy and patient support initiatives. The goal of the CCF’s advocacy group is to provide educational and emotional support for the cholangiocarcinoma (CCA) community of patients and caregivers, and to empower them with the knowledge and guidance needed to self-advocate.
New ICD-11 Codes for Cholangiocarcinoma
December 2021, Vol 2, No 4
The Cholangiocarcinoma Foundation (CCF) is encouraging healthcare professionals to support the adoption of the new International Classification of Diseases, 11th Revision (ICD-11), and its role in creating more robust epidemiological data for cholangio­carcinoma (CCA).
The International Cholangiocarcinoma Research Network: Educational and Research Achievements
By Reham Abdel-Wahab, MD, PhD
December 2021, Vol 2, No 4
In 2015, the Cholangiocarcinoma Foundation (CCF) launched the International Cholangiocarcinoma Research Network (ICRN). This network is a global collaborative of clinicians, researchers, and scientists from leading academic medical centers and research institutions working together to improve the prevention, early detection, treatment, and prognosis of cholangiocarcinoma (CCA).
Navigating Compassionate Use Options for Your Patients with Cholangiocarcinoma
By Melinda Bachini
September/October 2021, Vol 2, No 3
I believe that the most powerful and positive force in medicine is that of a self-advocating patient. At the Cholangiocarcinoma Foundation, we strive to connect, educate, and empower patients with cholangiocarcinoma (CCA) to partner with their care team in navigating the course of their treatment. However, we understand that the treatment options are extremely limited for many patients with CCA.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: